Scarica l'app Stockscreener
0.9622
10.92%
0.0947
Dopo l'orario di chiusura:
.97
0.0078
+0.81%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CTXR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.8675
Aprire:
$0.87
Volume 24 ore:
1.31M
Relative Volume:
1.61
Capitalizzazione di mercato:
$21.53M
Reddito:
-
Utile/perdita netta:
$-38.85M
Rapporto P/E:
-0.3325
EPS:
-2.8936
Flusso di cassa netto:
$-44.99M
1 W Prestazione:
+15.22%
1M Prestazione:
+25.74%
6M Prestazione:
-20.48%
1 anno Prestazione:
-37.92%
Intervallo 1D:
$0.8645
$1.03
Intervallo di 1 settimana:
$0.7792
$1.075
Portata 52W:
$0.63
$2.48
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Nome
Citius Pharmaceuticals Inc
Settore
Industria
Telefono
(908) 967-6676
Indirizzo
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
0.9622 | 21.53M | 0 | -38.85M | -44.99M | -2.8936 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-30 | Aggiornamento | D. Boral Capital | Hold → Buy |
| 2021-11-30 | Iniziato | Maxim Group | Buy |
Citius Pharmaceuticals Inc Borsa (CTXR) Ultime notizie
CTXR: Citius Pharmaceuticals Receives Consistent 'Buy' Rating fr - GuruFocus
CTXR: Citius Pharmaceuticals Receives Consistent 'Buy' Rating from D. Boral Capital | CTXR Stock News - GuruFocus
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - BioSpace
Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data - TipRanks
LYMPHIR combo shows activity in gynecologic cancers for Citius (CTXR) - Stock Titan
Citius Oncology reports positive phase 1 trial data for LYMPHIR - Investing.com India
Market Review: Is Citius Pharmaceuticals Inc in a long term uptrend2026 Trading Recap & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Bull Bear: Is Citius Pharmaceuticals Inc in a long term uptrendPortfolio Risk Summary & Verified Trade Idea Suggestions - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR - Yahoo Finance
33 Stocks That Should Double in 3 Years - Insider Monkey
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma - BioSpace
Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data - TipRanks
Citius Oncology Announces Positive Phase 1 LYMPHIR Data - TipRanks
Citius Pharmaceuticals subsidiary reports 86% ORR, 57% CR with LYMPHIR prior to CAR‑T in high‑risk DLBCL - TradingView
Citius Oncology (Nasdaq: CTXR) reports encouraging early LYMPHIR CAR-T combo results - Stock Titan
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma – Company Announcement - Financial Times
CTXR Should I Buy - Intellectia AI
Citius Pharmaceuticals CEO Leonard Mazur pursues growth through regulatory partnerships and rare disease therapies - Traders Union
Citius Pharmaceuticals, Inc. SEC 10-K Report - TradingView
CTXR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Movement Recap: Is Citius Pharmaceuticals Inc benefiting from interest rate changesJuly 2025 Opening Moves & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Citius Pharmaceuticals Secures $3.8M Via Net Operating Loss Program - New Jersey Business Magazine
Citius Pharmaceuticals Secures $3.8 Million Through New Jersey Economic Development Program - citybiz
Citius Pharmaceuticals (CTXR) Secures $3.8M Through NJ Tax Progr - GuruFocus
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program - PR Newswire
Citius Oncology (CTOR) Expands LYMPHIR Distribution to Europe Through Exclusive Agreement With Uniphar - Finviz
Market Pulse: Can Citius Pharmaceuticals Inc lead its sector in growthJuly 2025 Recap & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Resistance Check: Can GRNQ maintain sales growthWeekly Market Summary & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Patterns Watch: Will USAC outperform small cap indexesWeekly Loss Report & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Activity Recap: How does USBPRA perform in inflationary periodsBull Run & Weekly Momentum Stock Picks - baoquankhu1.vn
Analyst Downgrade: Is NVGS forming bullish engulfing patternsMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
Leonard Mazur: The Adventures of a Serial Entrepreneur - Pharmaceutical Executive
Dip Buying: Will Citius Pharmaceuticals Inc benefit from rate cutsJuly 2025 PreEarnings & Low Risk High Win Rate Picks - baoquankhu1.vn
CVI and Heights disclose 9.9% Citius Pharmaceuticals (CTXR) stake - Stock Titan
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - marketscreener.com
FOMO Trade: Is now the right time to enter MAPSMarket Growth Summary & Weekly Momentum Picks - baoquankhu1.vn
Can Citius Pharmaceuticals Inc. stock continue upward trendWall Street Watch & Free High Return Stock Watch Alerts - mfd.ru
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ (PR Newswire) - Aktiellt
Citius Oncology expands LYMPHIR access across Europe via exclusive Uniphar deal - Indian Pharma Post
Citius Oncology inks exclusive European distribution pact with Uniphar - MSN
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - The Malaysian Reserve
Citius Pharmaceuticals Q1 Earnings Report: What Investors Need to Know - Benzinga
Citius Pharmaceuticals Posts First Revenue Amid Listing Risk - TipRanks
Citius Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
CTXR: First revenue of $3.9M from LYMPHIR launch, narrowing net loss and strong pipeline progress - TradingView
Citius Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Citius Pharmaceuticals reports first revenue of $3.9 mln - TradingView
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ - PR Newswire
Risk Check: Should you buy the dip on ImmuCell CorporationWeekly Trend Summary & Precise Swing Trade Alerts - baoquankhu1.vn
Citius Oncology Signs Exclusive Distribution Agreement with Uniphar - Intellectia AI
Citius Pharmaceuticals Inc Azioni (CTXR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):